UBS Group’s Rhythm Pharmaceuticals RYTM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $20.1M | Sell |
231,650
-195,586
| -46% | -$19M | ﹤0.01% | 2576 |
|
|
2025
Q4 | $45.7M | Buy |
427,236
+6,900
| +2% | +$732K | 0.01% | 1706 |
|
|
2025
Q3 | $42.4M | Buy |
420,336
+167,754
| +66% | +$15.6M | 0.01% | 1798 |
|
|
2025
Q2 | $16M | Sell |
252,582
-19,526
| -7% | -$1.2M | ﹤0.01% | 2615 |
|
|
2025
Q1 | $14.4M | Buy |
272,108
+17,844
| +7% | +$990K | ﹤0.01% | 2661 |
|
|
2024
Q4 | $14.2M | Buy |
254,264
+177,630
| +232% | +$9.81M | ﹤0.01% | 2694 |
|
|
2024
Q3 | $4.01M | Buy |
76,634
+10,692
| +16% | +$512K | ﹤0.01% | 3298 |
|
|
2024
Q2 | $2.71M | Sell |
65,942
-105,623
| -62% | -$4.22M | ﹤0.01% | 3449 |
|
|
2024
Q1 | $7.43M | Buy |
171,565
+85,610
| +100% | +$3.75M | ﹤0.01% | 2553 |
|
|
2023
Q4 | $3.95M | Buy |
85,955
+59,304
| +223% | +$1.87M | ﹤0.01% | 3035 |
|
|
2023
Q3 | $611K | Sell |
26,651
-61,198
| -70% | -$1.37M | ﹤0.01% | 4504 |
|
|
2023
Q2 | $1.45M | Buy |
87,849
+3,772
| +4% | +$68.1K | ﹤0.01% | 3863 |
|
|
2023
Q1 | $1.5M | Sell |
84,077
-107,188
| -56% | -$2.69M | ﹤0.01% | 3723 |
|
|
2022
Q4 | $5.57M | Buy |
191,265
+178,630
| +1,414% | +$4.59M | ﹤0.01% | 2397 |
|
|
2022
Q3 | $309K | Buy |
12,635
+5,128
| +68% | +$95.4K | ﹤0.01% | 4751 |
|
|
2022
Q2 | $31K | Buy |
7,507
+7,007
| +1,401% | +$38.4K | ﹤0.01% | 6365 |
|
|
2022
Q1 | $6K | Sell |
500
-103,080
| -100% | -$905K | ﹤0.01% | 8986 |
|
|
2021
Q4 | $1.03M | Buy |
103,580
+22,610
| +28% | +$254K | ﹤0.01% | 4364 |
|
|
2021
Q3 | $1.06M | Buy |
80,970
+851
| +1% | +$13K | ﹤0.01% | 4158 |
|
|
2021
Q2 | $1.57M | Sell |
80,119
-46,731
| -37% | -$970K | ﹤0.01% | 3799 |
|
|
2021
Q1 | $2.7M | Buy |
126,850
+25,699
| +25% | +$745K | ﹤0.01% | 3244 |
|
|
2020
Q4 | $3.01M | Buy |
101,151
+58,894
| +139% | +$1.5M | ﹤0.01% | 2980 |
|
|
2020
Q3 | $916K | Buy |
42,257
+42,011
| +17,078% | +$963K | ﹤0.01% | 3705 |
|
|
2020
Q2 | $5K | Sell |
246
-5,579
| -96% | -$109K | ﹤0.01% | 7385 |
|
|
2020
Q1 | $89K | Buy |
5,825
+4,084
| +235% | +$73.1K | ﹤0.01% | 5391 |
|
|
2019
Q4 | $40K | Sell |
1,741
-33,231
| -95% | -$738K | ﹤0.01% | 6480 |
|
|
2019
Q3 | $755K | Buy |
34,972
+34,216
| +4,526% | +$734K | ﹤0.01% | 4215 |
|
|
2019
Q2 | $17K | Buy |
756
+570
| +306% | +$14.4K | ﹤0.01% | 6731 |
|
|
2019
Q1 | $5K | Sell |
186
-10,178
| -98% | -$293K | ﹤0.01% | 7177 |
|
|
2018
Q4 | $279K | Buy |
10,364
+5,408
| +109% | +$149K | ﹤0.01% | 4689 |
|
|
2018
Q3 | $145K | Buy |
4,956
+2,389
| +93% | +$75.5K | ﹤0.01% | 5285 |
|
|
2018
Q2 | $80K | Buy |
2,567
+1,624
| +172% | +$44.4K | ﹤0.01% | 5610 |
|
|
2018
Q1 | $19K | Sell |
943
-7,909
| -89% | -$210K | ﹤0.01% | 6448 |
|
|
2017
Q4 | $257K | Buy |
+8,852
| New | +$234K | ﹤0.01% | 4750 |
|
Other funds holding RYTM
RCM
BBA
VPM
VCM
PA
UBS Group's RYTM Position: Q1 2026 in Review
UBS Group reduced its Rhythm Pharmaceuticals (RYTM) stake by 46% in Q1 2026, selling an estimated $19M and leaving 231,650 shares worth $20.1M. The position accounts for ﹤0.01% of the portfolio, ranked #2576.
UBS Group first reported a position in RYTM in Q4 2017 and has held it in 34 quarters since. The position peaked at $45.7M in Q4 2025. 285 funds tracked by Wall St. Rank hold RYTM as of Q1 2026.
- UBS Group held 231,650 shares of Rhythm Pharmaceuticals worth $20.1M as of Q1 2026.
- UBS Group sold 195,586 Rhythm Pharmaceuticals shares in Q1 2026, an estimated $19M.
- Rhythm Pharmaceuticals made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #2576 holding.
- UBS Group first reported a position in Rhythm Pharmaceuticals in Q4 2017 and has held it in 34 quarters since.
- UBS Group's Rhythm Pharmaceuticals position peaked at $45.7M in Q4 2025.
- 285 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2026.
Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.